PPT-The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between

Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier Institut Jacques Cartier Massy France Patrick W Serruys Imperial College London UK. A clinical evaluation to compare the safety efficacy and performance of the Absorb everolimuseluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects wit The ABSORB III trial. Dean J. Kereiakes, MD, . Stephen . G. Ellis, MD, D. Christopher Metzger, MD, Ronald P. Caputo, MD, David G. Rizik, MD, Paul S. Teirstein, MD, Marc R. . Litt. , MD, . Annapoorna. clinico. in . tema. di BVS. Bernardo Cortese. Intv. ’ . Cardiology. , A.O. Fatebenefratelli. bcortese@gmail.com. b. ernardocortese.com. Bernardo Cortese MD FESC. A.O. Fatebenefratelli. The ABSORB Clinical Trial Program. Comparison of . Everolimus-­. Eluting . Absorb Bioresorbable Vascular. Scaffolds vs. . Everolimus-Eluting Metallic. . Stents:. One-Year Angiographic and Clinical Outcomes from the ABSORB China Trial. : . Two-Year Clinical . Results in Patients with Coronary Artery Disease Randomized to the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stents. Runlin . Gao, M.D.. On behalf of ABSORB China Investigators. trials“. Manish Narang. Sr. Medical Advisor-APJ, Abbott Vascular. 1. HAVING NOTHING . CAN MEAN EVERYTHING. 2. Why do we need a . bioresorbable scaffold?. LONG-TERM COMPLICATIONS OF PERMANENT STENTS. Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. Understanding:. The contraction of circular and longitudinal muscle layers of the small intestine mixes the food with enzymes and moves it along the gut. The pancreas secretes enzymes into the lumen of the small intestine. Results in Patients with Coronary Artery Disease Randomized to the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stents. Runlin . Gao, M.D.. On behalf of ABSORB China Investigators. Gregg W. Stone MD. Stephen G. Ellis MD and Dean J. Kereiakes MD. for the ABSORB IV Investigators. Disclosures. Chairman of the ABSORB global clinical trial program (uncompensated). Consultant to Reva, Inc.. Everolimus-­. Eluting . Absorb Bioresorbable Vascular. Scaffolds vs. . Everolimus-Eluting Metallic. . Stents:. One-Year Angiographic and Clinical Outcomes from the ABSORB China Trial. vs. 1.46 mm, . p < 0.0001; . IVUS showed lower post-procedure mean lumen area in BVS arm (4.9 vs. 5.7 mm. 2. , . p < 0.001. ). 1-year scaffold thrombosis in . two . BVS . patients; . no stent thrombosis in DES arm. Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention. Gregg W. Stone, MD. On behalf of Akiko Maehara, Ziad A. Ali, Claes Held, . Mitsuaki. Matsumura, Lars . Kjøller. Photosynthesis . Revision:. Answer these questions on photosynthesis from N5?. What is the photosynthesis word equation?. How many stages are there to photosynthesis?. Give 2 examples of the uses of the product of photosynthesis?.